Indinavir lactone

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 576673

CAS#: 913293-57-9

Description: Indinavir lactone is a protease inhibitor used as a component of highly active antiretroviral therapy to treat HIV/AIDS.

Chemical Structure

img
Indinavir lactone
CAS# 913293-57-9
Instruction

Theoretical Analysis

MedKoo Cat#: 576673
Name: Indinavir lactone
CAS#: 913293-57-9
Chemical Formula: C27H36N4O3
Exact Mass: 464.28
Molecular Weight: 464.610
Elemental Analysis: C, 69.80; H, 7.81; N, 12.06; O, 10.33

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Indinavir lactone; Indinavir sulfate specified impurity D

IUPAC/Chemical Name: (S)-1-(((2S,4R)-4-Benzyl-5-oxotetrahydrofuran-2-yl)methyl)-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide

InChi Key: MEAYEAZWSJPITC-SGNDLWITSA-N

InChi Code: InChI=1S/C27H36N4O3/c1-27(2,3)29-25(32)24-19-30(17-21-10-7-11-28-16-21)12-13-31(24)18-23-15-22(26(33)34-23)14-20-8-5-4-6-9-20/h4-11,16,22-24H,12-15,17-19H2,1-3H3,(H,29,32)/t22-,23+,24+/m1/s1

SMILES Code: CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H]3C[C@@H](Cc4ccccc4)C(=O)O3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 464.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Barrail-Tran A, Taburet AM, Poirier JM; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique. [Evidence-based therapeutic drug monitoring for indinavir]. Therapie. 2011 May-Jun;66(3):239-46. doi: 10.2515/therapie/2011035. Epub 2011 Aug 9. Review. French. PubMed PMID: 21819808.

2: Cressey TR, Plipat N, Fregonese F, Chokephaibulkit K. Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/AIDS, particularly in resource-limited settings. Expert Opin Drug Metab Toxicol. 2007 Jun;3(3):347-61. Review. PubMed PMID: 17539743.

3: Boyd M. Indinavir: the forgotten HIV-protease inhibitor. Does it still have a role? Expert Opin Pharmacother. 2007 May;8(7):957-64. Review. PubMed PMID: 17472541.

4: Fernández JM, Robles JE, Regojo JM, López J, Sánchez D, Arocena J, Rosell D, Zudaire JJ, Berián JM. [Renal lithiasis due to indinavir]. Rev Med Univ Navarra. 2002 Jul-Sep;46(3):28-32. Review. Spanish. PubMed PMID: 12685114.

5: García-Silva J, Almagro M, Peña-Penabad C, Fonseca E. Indinavir-induced retinoid-like effects: incidence, clinical features and management. Drug Saf. 2002;25(14):993-1003. Review. PubMed PMID: 12408731.

6: Rayner CR, Galbraith KJ, Marriott JL, Duncan GJ. A critical evaluation of the therapeutic range of indinavir. Ann Pharmacother. 2002 Jul-Aug;36(7-8):1230-7. Review. PubMed PMID: 12086558.

7: Wu DS, Stoller ML. Indinavir urolithiasis. Curr Opin Urol. 2000 Nov;10(6):557-61. Review. PubMed PMID: 11148725.

8: Famularo G, Di Toro S, Moretti S, De Simone C. Symptomatic crystalluria associated with indinavir. Ann Pharmacother. 2000 Dec;34(12):1414-8. Review. PubMed PMID: 11144699.

9: Benson JO, McGhee K, Coplan P, Grunfeld C, Robertson M, Brodovicz KG, Slater E. Fat redistribution in indinavir-treated patients with HIV infection: A review of postmarketing cases. J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):130-9. Review. PubMed PMID: 11103043.

10: The choice of HIV protease inhibitor: indinavir is currently the best option. Prescrire Int. 1999 Apr;8(40):55-60. Review. PubMed PMID: 10848067.

11: Gagnon RF, Alli AI, Watters AK, Tsoukas CM. Indinavir crystalluria. Kidney Int. 2006 Dec;70(12):2047. Review. PubMed PMID: 17136127.

12: Florence E, Schrooten W, Verdonck K, Dreezen C, Colebunders R. Rheumatological complications associated with the use of indinavir and other protease inhibitors. Ann Rheum Dis. 2002 Jan;61(1):82-4. Review. PubMed PMID: 11779768; PubMed Central PMCID: PMC1753893.

13: Youle M. Optimizing indinavir regimens. HIV Med. 2000 Jul;1 Suppl 2:7-11. Review. PubMed PMID: 11737366.

14: Plosker GL, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs. 1999 Dec;58(6):1165-203. Review. PubMed PMID: 10651394.

15: Perazella MA, Kashgarian M, Cooney E. Indinavir nephropathy in an AIDS patient with renal insufficiency and pyuria. Clin Nephrol. 1998 Sep;50(3):194-6. Review. PubMed PMID: 9776425.

16: Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci. 1997 Aug;19(4):159-75. Review. PubMed PMID: 9297727.

17: Chefchaouni MC, Thiounn N, Flam T, Zerbib M, Debré B. [Urinary calculi and indinavir sulfate in patients with HIV infection. Apropos of 4 cases]. J Urol (Paris). 1997;103(1-2):35-6. Review. French. PubMed PMID: 9765778.

18: Lacy MK, Abriola KP. Indinavir: a pharmacologic and clinical review of a new HIV protease inhibitor. Conn Med. 1996 Dec;60(12):723-7. Review. PubMed PMID: 9018893.